Caribbean Pharma Fieldwork: 2026 Complete Guide

Caribbean pharma fieldwork is the design, execution, and analysis of pharmaceutical research across the 21-island Caribbean region, encompassing healthcare professional (HCP) recruitment for in-depth interviews and surveys, patient journey research, over-the-counter (OTC) consumer studies, retail pharmacy audits, and key opinion leader (KOL) engagement. The region presents specific fieldwork challenges global agencies often misjudge: small specialist physician populations, four distinct language environments, country-specific regulatory frameworks, and a chronic disease burden that shapes both the research agenda and the available participant pool.

Why Caribbean Pharma Research Is Different

The Caribbean pharmaceutical research environment cannot be approached as a single market or extrapolated from Latin American or US Hispanic experience. Five factors make Caribbean pharma fieldwork distinct from research conducted in larger pharma markets.

Disease prevalence is structurally elevated. Diabetes prevalence across the Caribbean ranges from 12 to 16 percent of adults depending on the market, among the highest globally outside the Pacific Islands and significantly above the global average of approximately 9 percent. Hypertension prevalence runs 30 to 40 percent of adults across the region. Cardiovascular disease is the leading cause of death across most Caribbean markets. These prevalence rates create both research opportunity, since clinical questions around these conditions are highly relevant to the Caribbean patient and physician populations, and operational complexity, since patient recruitment for chronic disease studies must work within healthcare systems built for high-volume chronic disease management rather than research participation.

HCP universes are small and easily over-sampled. Jamaica has approximately 4,500 registered physicians of all specialties. Trinidad and Tobago has roughly 2,200. Barbados has approximately 600. Sub-specialist populations are correspondingly small: Jamaica has roughly 50 medical oncologists, Trinidad has fewer. A pharma research program that needs 15 oncologist interviews across the English-speaking Caribbean has already sampled one third of the available specialist pool. Programs that ignore this arithmetic create physician fatigue, reduce cooperation rates for subsequent programs, and risk producing non-representative samples.

Regulatory environments are country-specific and not harmonized. The Dominican Republic regulates pharmaceuticals through DIGEMAPS (Dirección General de Medicamentos, Alimentos y Productos Sanitarios). Jamaica regulates through the Ministry of Health Pharmaceutical and Therapeutic Services Division. Trinidad regulates through the Chemistry, Food and Drugs Division. Barbados regulates through the Drug Service of the Ministry of Health. Puerto Rico is fully US FDA aligned, making it operationally distinct from the rest of the Caribbean in ways that affect study design, consent language, and data handling.

Language and cultural contexts differ across the region. A Caribbean pharma program may need to operate simultaneously in English (Jamaica, Trinidad, Barbados, Bahamas), Spanish (Dominican Republic, Puerto Rico, Cuba), French Creole (Haiti, Martinique, Guadeloupe), and Dutch Creole or Papiamento (Curacao, Aruba, Suriname). Field operations need bilingual or trilingual capability in many programs. A patient experience study covering the broader Caribbean cannot rely on a single-language instrument.

Diaspora populations influence treatment-seeking behavior. Caribbean patients with serious conditions frequently travel to the United States, Canada, or the United Kingdom for advanced care, creating a treatment journey that does not begin and end within national borders. Research that ignores this dimension produces incomplete patient journey maps. Effective programs increasingly include diaspora interviews conducted from US or Canadian collection points alongside in-market work.

Caribbean Pharma Market Context

The Caribbean pharmaceutical market is small in absolute terms but strategically important for several segments of the global industry. Combined regional pharma sales sit in the USD 2-3 billion range, growing at 5-7 percent annually with significant variance by country.

Dominican Republic is the largest single market at approximately USD 800-900 million annually, driven by population scale (11 million), a fast-growing middle class, and proximity to the regional pharma manufacturing cluster. Jamaica follows at approximately USD 300 million. Trinidad and Tobago sits at roughly USD 200 million. Barbados and the smaller OECS islands collectively add another USD 250-300 million.

Puerto Rico represents a distinct case. Domestic pharma sales total approximately USD 400 million, but the island hosts one of the world's largest pharmaceutical manufacturing clusters, with over USD 60 billion in annual pharmaceutical exports. Major manufacturers including Pfizer, Eli Lilly, Bristol Myers Squibb, AstraZeneca, and Amgen maintain significant Puerto Rico operations. Pharma fieldwork in Puerto Rico therefore covers both consumer and HCP markets locally, and B2B research among manufacturing and regulatory operations teams at a scale unmatched elsewhere in the Caribbean.

Generic penetration varies significantly across markets. The Dominican Republic and Jamaica have high generic substitution rates. Barbados and the OECS retain higher branded pharmaceutical preference due to historical procurement patterns and physician training abroad.

Key Caribbean Pharma Research Use Cases

HCP Research

The most common pharma fieldwork engagement in the Caribbean involves healthcare professional research. Standard formats include:

In-depth interviews (IDIs) with specialists are the workhorse methodology for therapeutic area research. Typical Caribbean programs interview 8-15 specialists per country in cardiology, endocrinology, oncology, neurology, pulmonology, or other focus areas. IDIs run 45-60 minutes and probe treatment decisions, formulary preferences, competitive product perceptions, unmet needs, and clinical decision drivers.

Quantitative HCP surveys are used for market sizing, segmentation, and treatment-flow mapping. Caribbean HCP surveys typically deploy via CAPI (computer-assisted personal interviewing) in physician offices, CATI for time-pressed specialists, or online panel where physician digital adoption supports it, which is higher in younger cohorts and US-trained specialists.

Advisory boards with five to eight regional KOLs convene for half-day or full-day structured discussions on emerging therapies, treatment guidelines, or unmet needs.

Treatment pathway mapping combines HCP and patient input to build country-specific care journeys from symptom onset through diagnosis, treatment selection, adherence, and outcomes monitoring.

Patient Research

Patient-facing pharma research in the Caribbean focuses on the major chronic disease burden. Diabetes patient research is the most-commissioned therapeutic area given disease prevalence and the active pharmaceutical pipeline. Common study designs include treatment satisfaction studies, adherence research, insulin therapy initiation studies, and diabetic complications experience.

Hypertension and cardiovascular research follows similar patterns, often combining patient interviews with HCP qualitative work to understand the full treatment pathway. Oncology patient research is constrained by small patient populations per country but is increasingly important as Caribbean cancer survival rates improve. Mental health research is growing rapidly, driven by increasing regional focus and post-pandemic demand. Rare disease research includes sickle cell disease, which has high carrier rates across populations of African ancestry in the region.

OTC and Consumer Research

Over-the-counter pharmaceutical research in the Caribbean is operationally similar to FMCG consumer research with regulatory overlays. Common designs include concept testing for new OTC formulations, pricing research for analgesics, cold and flu, antacids, and supplements, pack design testing, brand health tracking for established OTC brands, and pharmacy channel preference research. The OTC market is dominated by Bayer Consumer Health, Sanofi Consumer Healthcare, Reckitt, GSK Consumer Health, and Johnson & Johnson Consumer, alongside strong regional and local brands.

Retail Pharmacy Audits

Pharmacy retail audits measure distribution coverage, planogram compliance, pricing accuracy, OTC and prescription availability, and competitor presence at the point of sale. Caribbean pharmacy retail spans formal chain pharmacies, independent pharmacies, and supermarket pharmacy counters. Comprehensive audit programs across a single country require 80-200 store visits depending on market structure.

KOL Engagement

Pharmaceutical companies increasingly engage Caribbean key opinion leaders for guideline development, regional treatment standardization, and clinical education. KOL identification, profiling, and engagement support is a specialized fieldwork niche requiring physician network knowledge that takes years to develop.

Methodologies Used in Caribbean Pharma Fieldwork

Regulatory and Ethical Considerations

Pharma fieldwork in the Caribbean follows the same fundamental ethical principles as research elsewhere but operates under country-specific institutional review and regulatory frameworks.

For market research that does not collect protected health information (PHI) and does not involve drug administration, formal IRB approval is generally not required, though informed consent and confidentiality protocols always apply. For patient research that involves medical records, clinical data, or PHI, country-specific ethics review applies.

Jamaica patient research routinely requires Ministry of Health ethics committee approval. The Dominican Republic uses CONABIOS (Consejo Nacional de Bioética en Salud) for biomedical research review. Trinidad uses University of the West Indies institutional review boards for academically-affiliated research. Puerto Rico patient research follows US FDA and Department of Health and Human Services frameworks essentially identical to mainland US research.

Pharmaceutical advertising and promotional research has its own regulatory considerations in some markets. Direct-to-consumer prescription pharmaceutical advertising is restricted or banned in most Caribbean markets, which affects how concept testing for prescription brand communications must be designed.

ICH-GCP (Good Clinical Practice) compliance is the standard for any research feeding clinical or regulatory submissions, though most market research does not rise to GCP standard.

Country-by-Country Considerations

Recruiting Healthcare Professionals in the Caribbean

HCP recruitment is the single most operationally demanding aspect of Caribbean pharma fieldwork. Effective recruitment requires several capabilities most generalist research firms lack.

Active HCP databases with regular maintenance are essential. Caribbean physician databases require continuous updating as specialists move between hospitals, retire, or change practice patterns. Lists more than 18 months old produce high refusal rates and frustration.

Honoraria management consistent with country standards is required. Specialist IDI honoraria in the Caribbean typically run USD 200-500 depending on specialty and program complexity. GP honoraria run USD 100-200. Honoraria must be processed in compliance with anti-bribery and pharmaceutical industry transparency standards including ABPI, PhRMA, and IFPMA frameworks.

Scheduling around clinical commitments. Caribbean specialists often combine public hospital, private practice, and teaching responsibilities. Recruitment that ignores clinical schedules has high cancellation rates. Effective firms work backward from physician availability rather than imposing fieldwork timing.

Bilingual capability where required. Spanish-language IDIs in the Dominican Republic and Puerto Rico, English-language across the rest of the region, with selective French or Creole capability for specific programs.

Confidentiality protocols. Caribbean specialist populations are small enough that research conversations can identify specific physicians by inference if not handled carefully. Reporting that maintains specialist anonymity is operationally non-trivial.

Patient Recruitment for Therapeutic Areas

Patient recruitment for Caribbean pharma research uses several channels depending on the therapeutic area and study design.

HCP-mediated patient recruitment works for many studies. Cooperating physicians refer eligible patients to research participation. This requires strong physician relationships and clear ethical separation between care and research.

Pharmacy-based recruitment screens patients picking up relevant prescriptions. Particularly useful for diabetes, hypertension, and other high-prevalence conditions.

Patient association networks are useful for less common conditions. Caribbean diabetes associations, cancer support organizations, and mental health advocacy groups can support recruitment for appropriately framed research.

Database recall of past research participants where consent permits. Hope Research Group maintains a regional patient research panel with appropriate re-contact consent.

What Caribbean Pharma Fieldwork Costs in 2026

Pharma fieldwork pricing in the Caribbean varies significantly based on therapeutic area, specialist availability, and country mix. The ranges below reflect 2026 pricing for programs designed and executed by regionally experienced firms.

Ranges include program design, recruitment, fieldwork execution, transcription and translation where applicable, ethics submission support, and reporting. Programs requiring formal GCP compliance price higher.

Common Mistakes in Caribbean Pharma Fieldwork

How to Choose a Caribbean Pharma Research Vendor

The signals that distinguish capable pharma research vendors in the Caribbean from generalist research firms include several practical markers.

Ask for:

• Years of pharma-specific fieldwork in the Caribbean with documented therapeutic area experience
• HCP database size and refresh cadence by country and specialty
• Specific specialist counts the firm has interviewed in your therapeutic area in the past 24 months
• Honoraria management documentation and pharmaceutical industry compliance frameworks
• Ethics submission experience with specific country IRBs the firm has worked with
• References from comparable pharma sponsors willing to discuss program execution
• Bilingual operational capability demonstrated through completed programs, not claimed competency
• Sample reports from comparable Caribbean pharma programs (de-identified)

Vendors that cannot answer these questions with specifics should be approached with caution. Pharma fieldwork is operationally demanding and the firms that do it well have built capacity over many years across multiple therapeutic areas.